Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being.
We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) as an active control. The primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled RCT. We will also measure heart rate variability (HRV), an easily obtained biomarker of vagus nerve stimulation (VNS), in correspondence to intervention response.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active DLPFC tDCS | Active Comparator | 20 daily 20-minute sessions of active tDCS. |
|
| Active taVNS | Experimental | 20 daily 60-minute sessions of active taVNS. |
|
| Active tcVNS | Experimental | 20 daily 20-minute sessions of active tcVNS. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) | Device | tDCS is a noninvasive brain stimulation device that modulates brain activity delivering a low-intensity electrical current. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants who Complete Home-Based taVNS or tcVNS Sessions | Assessed among participants in the taVNS or tcVNS arms only. | Up to Week 4 (End of Intervention) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in SymptoMScreen Score | SymptoMScreen is a self-report tool to assess overall symptom burden. | Baseline, Week 4 (End of Intervention) |
| Change in Multiple Sclerosis Impact Scale (MSIS-29) Score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Leigh Charvet, PhD | NYU Langone Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NYU Langone Health | New York | New York | 10017 | United States |
No plan to share IPD.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS) | Device | taVNS is a noninvasive peripheral nerve stimulation device that modulates vagus nerve activity delivering a low-intensity electrical current (< 5mA) through hydrogel electrodes to the left auricular branch of the vagus nerve. |
|
| Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS) | Device | tcVNS is a noninvasive peripheral nerve stimulation device that modulates vagus nerve activity delivering a low-intensity electrical current (< 5mA) through cervical hydrogel electrodes to the left cervical branch of the vagus nerve. |
|
12-item self-report scale to assess symptom burden regarding neurological domains and the psychological impact of MS. Each item is rated on a 7-point Likert scale from 0 to 6. The item responses are summed to calculate a total score ranging from 0 to 72, with a higher score indicating more severe symptom limitations
| Baseline, Week 4 (End of Intervention) |
| Change in Memorial Symptom Assessment Scale (MSAS) Score | 32-item symptom self-report rating scale to better understand the symptom severity, symptom frequency, and distress from common symptoms. The total MSAS score is the average of the symptom scores for all 32 symptoms and ranges from 0 to 4. Higher scores indicate greater impact from symptoms. | Baseline, Week 4 (End of Intervention) |
| Change in Kessler Psychological Distress Scale (K10) Score | 10-item questionnaire to assess psychological distress over a recent period of the past 4 weeks focusing on anxiety and depressive symptoms. Each item is rated on a 5-point Likert scale from 1-5. The total score is the sum of responses and ranges from 10-50; higher scores indicate more severe mental disorder. | Baseline, Week 4 (End of Intervention) |
| Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form Score | 8-item qualitative self-report questionnaire regarding functions of sleep and wakefulness such as perceived sleep quality, sleep depth, and restfulness after sleep in the past 7 days. Each item is rated on a scale from 1-5. The total score is the sum of responses and ranges from 8-40; a higher score indicates more severe sleep disturbances. | Baseline, Week 4 (End of Intervention) |
| Change in PROMIS Fatigue - Short Form 7a Score | 7-item self-report tool assessing fatigue severity and impact. Each item is rated on a scale from 1-5. The total score is the sum of responses and ranges from 7-35; higher scores indicate greater fatigue. | Baseline, Week 4 (End of Intervention) |
| Change in PROMIS Pain Intensity - Short Form 3a Score | 3-item tool to evaluate quantitative participant experiences of pain intensity both over the past 7 days and at the time of completing the self-report assessment. Each item is rated on a scale from 1-5. The total score is the sum of responses and ranges from 3-15; higher scores indicate greater pain intensity. | Baseline, Week 4 (End of Intervention) |
| Change in General Anxiety Disorder (GAD-7) Score | 7-item self-report questionnaire to screen for generalized anxiety in addition to assessing severity of anxiety symptoms. Each item is rated on a scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0-21; higher scores indicate more prevalent symptoms of anxiety. | Baseline, Week 4 (End of Intervention) |
| Change in Composite Autonomic Symptom Score-31 (COMPASS-31) Score | 31-item scale measuring autonomic symptoms in six domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor functions. A total score from 0-100 is generated from the item responses; higher scores indicate more severe autonomic dysfunction. | Baseline, Week 4 (End of Intervention) |
| Change in Patient Health Questionnaire (PHQ-9) Score | 9-item self-report questionnaire to screen for depressive disorder and furthermore, severity. Each item is rated on a scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0-27; higher scores indicate greater severity of depressive symptoms. | Baseline, Week 4 (End of Intervention) |
| Change in Nine-Hole Peg Test (9HPT) Score | Assessment of manual dexterity and fine motor coordination in people with MS, using both dominant and non-dominant hands. The score is measured by the number of seconds it takes for a person to place and remove nine pegs from a pegboard, with a lower score (in seconds) indicating better dexterity and faster completion time. | Baseline, Week 4 (End of Intervention) |
| Change in Heart Rate Variability (HRV) | Assessed using the Chest Strap Polar H10 HR sensor. | Baseline, Week 4 (End of Intervention) |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided